Pharmaceutical companies brokered fewer deals with generic competitors to delay sales of cheaper drugs in fiscal year 2014, the first full fiscal year after the U.S. Supreme Court ruled that such deals, known as “pay-for-delay” deals or “reverse payment settlements,” could violate antitrust laws.
According to data released on Wednesday by the U.S. Federal Trade Commission, drug companies reached 21 agreements that the FTC labeled as “potential” pay-for-delay deals. That’s a drop from 29 in fiscal year 2013 and 40 in fiscal year 2012.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
